Plan debates typically return to scheduling and bans. India and the United States both of those experience versions of the exact same problem: no matter whether to impose broader, course-vast controls around fentanyl analogs and their precursors, or to help keep compound-by-substance scheduling which will lag powering traffickers’ innovation.What